稳定期COPD中LABA与LAMA疗效与安全性的系统评价与Meta分析
结果显示LAMA在减少急性加重和不良事件方面优于LABA,而谷值FEV1、TDI评分和SGRQ评分无显著差异。
要点
- 稳定期COPD患者中,LAMA较LABA减少急性加重(OR 0.84,95%CI 0.74-0.94,P=0.003)。
- LAMA较LABA不良事件更少(OR 0.92,95%CI 0.86-0.97,P=0.005)。
- 谷值FEV1、TDI评分与SGRQ评分在LABA与LAMA间无显著差异。
核心结论
- 在稳定期COPD患者中,与LABA相比,LAMA与急性加重减少和不良事件更少相关。
主要发现
- LAMA较LABA减少急性加重(OR 0.84,95%CI 0.74-0.94,P=0.003)。
- LAMA较LABA不良事件更少(OR 0.92,95%CI 0.86-0.97,P=0.005)。
- 谷值FEV1、TDI评分和SGRQ评分在两组间无显著差异。
关键数值与推荐
- 急性加重比较:OR 0.84,95%CI 0.74-0.94,P=0.003, favoring LAMA。
- 不良事件比较:OR 0.92,95%CI 0.86-0.97,P=0.005, favoring LAMA。
临床怎么用
- 稳定期COPD初始选择支气管扩张剂时,可考虑LAMA以更好减少急性加重和不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several long-acting bronchodilators have been developed and are widely used as first-line treatment in patients with stable chronic obstructive pulmonary disease (COPD). However, the initial choice of therapy is still uncertain. The aim of this study was to examine the clinical efficacy and safety of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) in patients with stable COPD. We searched several databases and manufacturers' websites to identify relevant randomized clinical trials for meta-analysis. Outcomes of interest were trough forced expiratory volume in 1 s (FEV1 ), acute exacerbations, transitional dyspnoea index (TDI) score, St George's Respiratory Questionnaire (SGRQ) score and adverse events. Sixteen trials with a total of 22 872 patients were included in this study. Compared with LABA, LAMA were associated with a greater reduction in acute exacerbations (OR: 0.84, 95% CI: 0.74-0.94, P = 0.003) and fewer adverse events (OR: 0.92, 95% CI: 0.86-0.97, P = 0.005). There were no significant differences in trough FEV1 , TDI and SGRQ scores. In patients with stable COPD, LAMA were associated with a greater reduction in acute exacerbations and fewer adverse effects compared with LABA.
引用
- Chen WC, Huang CH, Sheu CC, et al. Long-acting beta2-agonists versus long-acting muscarinic antagonists in patients with stable COPD: A systematic review and meta-analysis of randomized controlled trials. Respirology. 2017. PMID: 28654201. doi:10.1111/resp.13100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。